Karyopharm Historical Balance Sheet

KPTI Stock  USD 0.73  0.04  5.19%   
Trend analysis of Karyopharm Therapeutics balance sheet accounts such as Property Plant And Equipment Net of 3 M provides information on Karyopharm Therapeutics' total assets, liabilities, and equity, which is the actual value of Karyopharm Therapeutics to its prevalent stockholders. By breaking down trends over time using Karyopharm Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Karyopharm Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Karyopharm Therapeutics is a good buy for the upcoming year.

Karyopharm Therapeutics Inventory

1.58 Million

  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

About Karyopharm Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Karyopharm Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Karyopharm Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Karyopharm Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Karyopharm currently owns. An asset can also be divided into two categories, current and non-current.

Karyopharm Therapeutics Balance Sheet Chart

As of now, Karyopharm Therapeutics' Accounts Payable is increasing as compared to previous years. The Karyopharm Therapeutics' current Cash is estimated to increase to about 101.6 M, while Total Assets are projected to decrease to under 238.3 M.

Total Assets

Total assets refers to the total amount of Karyopharm Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Karyopharm Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Karyopharm Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Karyopharm Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.
Most accounts from Karyopharm Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.As of now, Karyopharm Therapeutics' Accounts Payable is increasing as compared to previous years. The Karyopharm Therapeutics' current Cash is estimated to increase to about 101.6 M, while Total Assets are projected to decrease to under 238.3 M.
 2021 2022 2023 2024 (projected)
Cash190.5M135.2M52.2M101.6M
Accounts Payable1.6M2.8M3.1M3.5M

Karyopharm Therapeutics balance sheet Correlations

0.50.630.090.740.440.16-0.740.390.740.480.440.370.980.740.660.570.880.670.480.990.330.63-0.50.57-0.78
0.50.86-0.660.540.640.57-0.81-0.20.430.270.680.210.390.780.840.860.670.860.410.47-0.210.03-0.870.84-0.78
0.630.86-0.470.630.650.52-0.830.070.460.290.580.140.550.830.750.830.750.820.380.610.140.25-0.760.83-0.81
0.09-0.66-0.47-0.05-0.21-0.810.570.530.160.22-0.34-0.230.17-0.48-0.67-0.54-0.29-0.68-0.310.080.660.520.77-0.660.53
0.740.540.63-0.050.330.38-0.670.360.310.360.24-0.130.680.680.550.60.770.580.330.730.340.44-0.390.67-0.68
0.440.640.65-0.210.330.07-0.470.180.490.660.740.520.320.460.470.730.50.47-0.080.370.210.2-0.540.36-0.48
0.160.570.52-0.810.380.07-0.72-0.2-0.28-0.130.070.070.10.690.680.470.490.730.560.18-0.28-0.08-0.650.8-0.67
-0.74-0.81-0.830.57-0.67-0.47-0.72-0.09-0.41-0.27-0.46-0.36-0.67-0.97-0.94-0.77-0.92-0.97-0.66-0.740.09-0.220.88-0.940.99
0.39-0.20.070.530.360.18-0.2-0.090.170.33-0.33-0.050.40.25-0.18-0.080.22-0.10.110.360.780.630.250.03-0.07
0.740.430.460.160.310.49-0.28-0.410.170.310.60.410.750.380.460.510.50.430.130.740.130.31-0.390.27-0.45
0.480.270.290.220.360.66-0.13-0.270.330.310.510.440.360.250.210.310.430.18-0.020.360.330.47-0.250.07-0.34
0.440.680.58-0.340.240.740.07-0.46-0.330.60.510.580.340.320.640.740.480.57-0.070.4-0.22-0.02-0.680.31-0.53
0.370.210.14-0.23-0.130.520.07-0.36-0.050.410.440.580.310.250.50.340.410.430.110.33-0.240.03-0.520.11-0.43
0.980.390.550.170.680.320.1-0.670.40.750.360.340.310.680.590.460.810.60.50.990.360.66-0.390.5-0.7
0.740.780.83-0.480.680.460.69-0.970.250.380.250.320.250.680.840.70.870.90.720.730.080.36-0.780.94-0.93
0.660.840.75-0.670.550.470.68-0.94-0.180.460.210.640.50.590.840.820.840.990.550.66-0.320.04-0.950.86-0.95
0.570.860.83-0.540.60.730.47-0.77-0.080.510.310.740.340.460.70.820.690.820.080.55-0.07-0.04-0.810.77-0.78
0.880.670.75-0.290.770.50.49-0.920.220.50.430.480.410.810.870.840.690.860.580.870.070.37-0.750.79-0.95
0.670.860.82-0.680.580.470.73-0.97-0.10.430.180.570.430.60.90.990.820.860.590.67-0.240.09-0.940.92-0.97
0.480.410.38-0.310.33-0.080.56-0.660.110.13-0.02-0.070.110.50.720.550.080.580.590.5-0.10.41-0.460.62-0.61
0.990.470.610.080.730.370.18-0.740.360.740.360.40.330.990.730.660.550.870.670.50.30.59-0.480.58-0.77
0.33-0.210.140.660.340.21-0.280.090.780.130.33-0.22-0.240.360.08-0.32-0.070.07-0.24-0.10.30.770.44-0.130.1
0.630.030.250.520.440.2-0.08-0.220.630.310.47-0.020.030.660.360.04-0.040.370.090.410.590.770.140.09-0.23
-0.5-0.87-0.760.77-0.39-0.54-0.650.880.25-0.39-0.25-0.68-0.52-0.39-0.78-0.95-0.81-0.75-0.94-0.46-0.480.440.14-0.830.89
0.570.840.83-0.660.670.360.8-0.940.030.270.070.310.110.50.940.860.770.790.920.620.58-0.130.09-0.83-0.89
-0.78-0.78-0.810.53-0.68-0.48-0.670.99-0.07-0.45-0.34-0.53-0.43-0.7-0.93-0.95-0.78-0.95-0.97-0.61-0.770.1-0.230.89-0.89
Click cells to compare fundamentals

Karyopharm Therapeutics Account Relationship Matchups

Karyopharm Therapeutics balance sheet Accounts

201920202021202220232024 (projected)
Total Assets295.0M313.1M305.3M358.2M240.4M238.3M
Other Current Liab41.4M(6.4M)67.5M57.4M59.7M62.7M
Total Current Liabilities46.4M297K73.7M65.9M69.5M73.0M
Total Stockholder Equity49.8M50.5M(79.7M)(16.7M)(136.2M)(129.4M)
Property Plant And Equipment Net3.0M2.2M1.6M7.4M4.9M3.0M
Current Deferred Revenue2.3M297K69.1M25.1M28.8M15.7M
Net Debt(19.0M)32.0M(21.2M)37.8M124.8M131.0M
Retained Earnings(873.3M)(1.1B)(1.2B)(1.3B)(1.5B)(1.4B)
Accounts Payable985K4.5M1.6M2.8M3.1M3.5M
Cash128.9M85.9M190.5M135.2M52.2M101.6M
Non Current Assets Total21.3M23.5M47.2M31.4M6.5M6.2M
Non Currrent Assets Other16.2M(2.9M)44.9M23.4M1.6M1.6M
Other Assets714K34.3M45.6M633K1.00.95
Cash And Short Term Investments264.0M273.5M228.6M278.0M191.4M201.7M
Common Stock Shares Outstanding62.0M72.0M75.2M81.9M114.2M119.9M
Liabilities And Stockholders Equity295.0M313.1M305.3M358.2M240.4M238.3M
Non Current Liabilities Total245.2M262.2M385.0M374.8M307.2M322.5M
Other Current Assets1.5M559K20.4M20.9M12.5M13.1M
Other Stockholder Equity923.1M1.1B1.1B1.3B1.4B748.9M
Total Liab245.2M262.5M385.0M374.8M376.6M395.5M
Property Plant And Equipment Gross13.7M11.6M1.6M1.1M11.4M12.0M
Total Current Assets273.7M289.5M258.1M326.8M233.9M215.6M
Accumulated Other Comprehensive Income(37K)518K191K(638K)(161K)(169.1K)
Short Term Debt1.6M1.9M4.6M5.7M6.6M8.5M
Property Plant Equipment3.0M2.2M1.6M1.1M1.3M2.2M
Net Tangible Assets49.8M50.5M(79.7M)(16.7M)(15.0M)(14.2M)
Long Term Debt109.9M117.9M169.3M170.1M170.9M179.5M
Retained Earnings Total Equity(873.3M)(1.1B)(1.2B)(1.3B)(1.2B)(1.1B)
Short Term Investments133.1M163.3M38.2M142.8M139.2M115.6M
Capital Surpluse923.1M1.1B1.1B1.3B1.5B824.8M
Other Liab8.5M75.8M144.6M215.7M248.0M260.4M
Net Invested Capital159.6M168.5M169.3M170.1M34.7M33.0M
Net Working Capital232.2M216.3M201.9M284.3M164.4M233.5M
Short Long Term Debt Total111.5M119.8M169.3M173.0M177.0M162.5M

Currently Active Assets on Macroaxis

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
1.247
Quarterly Revenue Growth
0.077
Return On Assets
(0.34)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.